{"title":"Insights Into Liver Transplant Disparities.","authors":"Veronica Loy","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 9","pages":"573-575"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12853626/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146108489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Update on Nivolumab Plus Ipilimumab Combination Therapy for Patients With Hepatocellular Carcinoma.","authors":"Peter R Galle","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 9","pages":"583-585"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12853627/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146108523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"One-Year Comparative Effectiveness and Safety of Upadacitinib Versus Risankizumab for CD.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 7 Suppl 5","pages":"9-10"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397778/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
For eosinophilic esophagitis (EoE), the most well researched of the eosinophilic gastrointestinal diseases (EGIDs), there is a plethora of knowledge for its diagnosis and management; however, much less guidance is available for the non-EoE EGIDs. Efforts have been made to characterize the clinical features, epidemiology, diagnosis, and natural history of EGIDs, as the frequency of the non-EoE EGIDs has continued to rise. The diagnosis of the different non-EoE EGIDs, eosinophilic gastritis, enteritis, and colitis, can be challenging because of their rarity and heterogeneous presentations which can lead to delayed diagnosis and poor health-related quality of life in affected patients. Guidelines for histologic evaluation and diagnostic criteria for non-EoE EGID are actively being developed. Effective management of non-EoE EGIDs is possible with currently available assessments and therapies, with more treatments on the horizon, highlighting the need for improved understanding of non-EoE EGIDs. This article will review the diagnosis and management of the non-EoE EGIDs, focusing on the consensus nomenclature, nuances in diagnosis, and management options.
{"title":"Eosinophils Beyond the Esophagus: A Review of Non-EoE Eosinophilic Gastrointestinal Diseases.","authors":"Angela Y Lam, Nirmala Gonsalves","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>For eosinophilic esophagitis (EoE), the most well researched of the eosinophilic gastrointestinal diseases (EGIDs), there is a plethora of knowledge for its diagnosis and management; however, much less guidance is available for the non-EoE EGIDs. Efforts have been made to characterize the clinical features, epidemiology, diagnosis, and natural history of EGIDs, as the frequency of the non-EoE EGIDs has continued to rise. The diagnosis of the different non-EoE EGIDs, eosinophilic gastritis, enteritis, and colitis, can be challenging because of their rarity and heterogeneous presentations which can lead to delayed diagnosis and poor health-related quality of life in affected patients. Guidelines for histologic evaluation and diagnostic criteria for non-EoE EGID are actively being developed. Effective management of non-EoE EGIDs is possible with currently available assessments and therapies, with more treatments on the horizon, highlighting the need for improved understanding of non-EoE EGIDs. This article will review the diagnosis and management of the non-EoE EGIDs, focusing on the consensus nomenclature, nuances in diagnosis, and management options.</p>","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 8","pages":"511-519"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397780/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Corticosteroid-Sparing Effects of Treatment With Guselkumab in Patients With Moderately to Severely Active CD: Phase 3 GRAVITI Study Results Through Week 48.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 7 Suppl 5","pages":"10-12"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397773/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The use of terlipressin in the treatment of hepatorenal syndrome type 1 (HRS-1) in patients with advanced cirrhosis wait-listed for liver transplant (LT) has been controversial. Successful treatment lowers patients' Model for End-Stage Liver Disease (MELD) score and hence their LT priority. Terlipressin's potential ischemic side effects and risks for respiratory failure in susceptible patients lend support to directly proceed to LT. However, responders to terlipressin have better post-LT survival with lower incidences of post-LT chronic kidney disease and need for renal replacement therapy (RRT). Available data suggest that terlipressin responders have not all been impacted negatively. HRS-1 itself confers a greater negative effect on survival when compared with patients with the same MELD score but without HRS-1; therefore, various countries except the United States have strategies to preserve the wait-list position of terlipressin responders. The MELD lock strategy uses the patient's pre-terlipressin MELD score to maintain their wait-list position indefinitely; a modified MELD lock system requires re-evaluation of the patient's eligibility status every 3 months. Patients taking long-term terlipressin for recurrent HRS are treated as needing RRT in assessing their LT priority. The United States considers that more data are needed before devising its own system for managing wait-listed terlipressin responders. Current data suggest that treating and reversing HRS in wait-listed patients is the appropriate course of action. This article will review the pros and cons of using terlipressin in LT wait-listed patients with HRS and the various strategies practiced by different countries to ensure equitable access to LT.
{"title":"Use of Terlipressin in Liver Transplant Candidates.","authors":"Nicodemus Ong, Florence Wong","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The use of terlipressin in the treatment of hepatorenal syndrome type 1 (HRS-1) in patients with advanced cirrhosis wait-listed for liver transplant (LT) has been controversial. Successful treatment lowers patients' Model for End-Stage Liver Disease (MELD) score and hence their LT priority. Terlipressin's potential ischemic side effects and risks for respiratory failure in susceptible patients lend support to directly proceed to LT. However, responders to terlipressin have better post-LT survival with lower incidences of post-LT chronic kidney disease and need for renal replacement therapy (RRT). Available data suggest that terlipressin responders have not all been impacted negatively. HRS-1 itself confers a greater negative effect on survival when compared with patients with the same MELD score but without HRS-1; therefore, various countries except the United States have strategies to preserve the wait-list position of terlipressin responders. The MELD lock strategy uses the patient's pre-terlipressin MELD score to maintain their wait-list position indefinitely; a modified MELD lock system requires re-evaluation of the patient's eligibility status every 3 months. Patients taking long-term terlipressin for recurrent HRS are treated as needing RRT in assessing their LT priority. The United States considers that more data are needed before devising its own system for managing wait-listed terlipressin responders. Current data suggest that treating and reversing HRS in wait-listed patients is the appropriate course of action. This article will review the pros and cons of using terlipressin in LT wait-listed patients with HRS and the various strategies practiced by different countries to ensure equitable access to LT.</p>","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 8","pages":"519-527"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397782/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Impact of Immunogenicity on 2-Year Clinical Outcomes in Patients With Moderate-to-Severe CD Treated With Subcutaneous Infliximab: A Post Hoc Analysis of the Phase 3 LIBERTY-CD Study.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 7 Suppl 5","pages":"18-19"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397775/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Fibroblast Growth Factor 21 Agonists for the Treatment of Patients With Metabolic Dysfunction-Associated Steatohepatitis.","authors":"Philip Newsome","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 8","pages":"489-491"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397783/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Exploring the Use of Terlipressin in Candidates for Liver Transplant.","authors":"Gary R Lichtenstein","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 8","pages":"467"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397784/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号